Therapy Areas: Oncology
Onxeo reports on AGM 2018
17 May 2018 -

Biotechnology company Onxeo S.A. (CPH:ONXEO)(Paris:ONXEO) announced on Wednesday that the Ordinary Shareholders' General Meeting approved all the resolutions submitted to its vote, with over 88% of favourable votes.

Reportedly, in particular, the Ordinary General Meeting renewed the terms of office of Thomas Hofstaetter as director. Hofstaetter is chair of the Onxeo's compensation and business development committees.

According to the company, the quorum of 20.07% did not permit the resolutions to be discussed on an extraordinary basis.

As a result, the company's shareholders are invited to attend an

Extraordinary General Meeting on the second notice which will be held on 19 June 2018 at the company's headquarters in Paris, France, to deliberate on the same agenda.

Onxeo clarified that the votes of the shareholders who voted by mail for the first general meeting remain valid and counted for the general meeting on the second notice.

Onxeo develops oncology drugs based on DNA-targeting and epigenetics, two of the most sought-after mechanisms of action in cancer treatment currently.

Login
Username:

Password: